Interferon-γ and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important Zygomycetes

被引:124
作者
Gil-Lamaignere, C
Simitsopoulou, M
Roilides, E
Maloukou, A
Winn, RM
Walsh, TJ
机构
[1] NCI, Immunocompromised Host Sect, Pediat Oncol Branch, Bethesda, MD 20892 USA
[2] Aristotle Univ Thessaloniki, Hippokrat Hosp, Dept Pediat 3, GR-54006 Thessaloniki, Greece
关键词
D O I
10.1086/428503
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Zygomycetes cause serious invasive infections, predominantly in immunocompromised and diabetic patients with poor prognoses and limited therapeutic options. We compared the antifungal function of human polymorphonuclear leukocytes (PMNLs) against hyphae of Rhizopus oryzae and R. microsporus, the most frequently isolated zygomycetes, with that against the less frequently isolated Absidia corymbifera. We then evaluated the effects of interferon (IFN)-gamma and granulocyte-macrophage colony-stimulating factor (GM-CSF), alone or combined, on PMNL antifungal function against these zygomycetes. Both PMNL oxidative burst in response to hyphae and PMNL-induced hyphal damage were significantly lower in response to Rhizopus species than in response to A. corymbifera. Incubation of PMNLs with IFN-gamma and GM-CSF alone or combined for 22 h increased the PMNL-induced hyphal damage of all 3 species. The treatment of PMNLs with the combination of IFN-gamma and GM-CSF significantly increased the release of tumor necrosis factor-alpha in response to R. microsporus and A. corymbifera hyphae. IFN-gamma significantly reduced interleukin-8 release in response to all zygomycetes. Although Rhizopus species demonstrate a decreased susceptibility to the antifungal activity of human PMNLs, in comparison with A. corymbifera, IFN-gamma and GM-CSF augment the hyphal damage of all 3 zygomycetes, suggesting a role for IFN-gamma and GM-CSF in the management of invasive zygomycosis.
引用
收藏
页码:1180 / 1187
页数:8
相关论文
共 60 条
[1]   Granulocyte-macrophage colony-stimulating factor-activated signaling pathways in human neutrophils - Selective activation of Jak2, Stat3, and Stat5B [J].
Al-Shami, A ;
Mahanna, W ;
Naccache, PH .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (02) :1058-1063
[2]   GAMMA-INTERFERON IS ABLE TO ENHANCE THE OXIDATIVE-METABOLISM OF HUMAN-NEUTROPHILS [J].
BERTON, G ;
ZENI, L ;
CASSATELLA, MA ;
ROSSI, F .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1986, 138 (03) :1276-1282
[3]   Ten years' experience in zygomycosis at a tertiary care centre in India [J].
Chakrabarti, A ;
Das, A ;
Sharma, A ;
Panda, N ;
Das, S ;
Gupta, KL ;
Sakhuja, V .
JOURNAL OF INFECTION, 2001, 42 (04) :261-266
[4]   Effect in vitro of gamma interferon and interleukin-10 on generation of oxidizing species by human granulocytes [J].
Chaves, MM ;
Silvestrini, AA ;
SilvaTeixeira, DN ;
NogueiraMachado, JA .
INFLAMMATION RESEARCH, 1996, 45 (07) :313-315
[5]  
CHINN RYW, 1982, INFECT IMMUN, V38, P1123, DOI 10.1128/IAI.38.3.1123-1129.1982
[6]   Mechanisms and target sites of damage in killing of Candida albicans hyphae by human polymorphonuclear neutrophils [J].
Christin, L ;
Wysong, DR ;
Meshulam, T ;
Wang, SY ;
Diamond, RD .
JOURNAL OF INFECTIOUS DISEASES, 1997, 176 (06) :1567-1578
[7]   Efficacy of interferon-γ and amphotericin B for the treatment of systemic murine histoplasmosis [J].
Clemons, KV ;
Lutz, JE ;
Stevens, DA .
MICROBES AND INFECTION, 2001, 3 (01) :3-10
[8]   Treatment of orogastrointestinal candidosis in SCID mice with fluconazole alone or in combination with recombinant granulocyte colony-stimulating factor or interferon-γ [J].
Clemons, KV ;
Stevens, DA .
MEDICAL MYCOLOGY, 2000, 38 (03) :213-219
[9]   Effects of in vitro and in vivo cytokine treatment, leucapheresis and irradiation on the function of human neutrophils: Implications for white blood cell transfusion therapy [J].
Cohen, DM ;
Bhalla, SC ;
Anaissie, EJ ;
Hester, JP ;
Savary, CA ;
Rex, JH .
CLINICAL AND LABORATORY HAEMATOLOGY, 1997, 19 (01) :39-47
[10]  
Dale DC, 1998, AM J HEMATOL, V57, P7, DOI 10.1002/(SICI)1096-8652(199801)57:1<7::AID-AJH2>3.0.CO